Persistence of Seropositivity Among Persons Vaccinated for Hepatitis A During Infancy by Maternal Antibody Status: 15-Year Follow-up

Details

• Alternative Title:
  Hepatology
• Personal Author:
  Spradling, Philip R. ; Bulkow, Lisa R. ; Negus, Susan E. ; Homan, Chriss ; Bruce, Michael G. ; McMahon, Brian J.
• Description:
  The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti-HAV at intervals through age 15-16 years among three groups of Alaskan Native children who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti-HAV status. Seropositivity (anti-HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty-three children participated in the study; follow-up did not differ significantly by vaccine group or maternal anti-HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15-16 years among group 1 children, who initiated vaccination at age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti-HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15-16 years, 84% were predicted to remain so for ≥30 years.|Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15-16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody-positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow-up of this cohort.
• Subjects:
  Adolescent Age Factors Alaska Female Follow-Up Studies Hepatitis A Hepatitis A Vaccines Humans Indians, North American Infant Maternal Exposure

  More +
• Source:
  Hepatology. 63(3):703-711
• Pubmed ID:
  26637987
• Pubmed Central ID:
  PMC6459008
• Document Type:
  Journal Article
• Funding:
  CC999999/Intramural CDC HHSUnited States/
• Volume:
  63
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:d129d1335610fdaa255b3e9212e483a479282ce3f86fe7bb824aab77ec9a2c0b
• Download URL:
  https://stacks.cdc.gov/view/cdc/77506/cdc_77506_DS1.pdf
• File Type:
  [PDF - 148.54 KB ]